IT201800003875A1 - Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi - Google Patents

Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi Download PDF

Info

Publication number
IT201800003875A1
IT201800003875A1 IT102018000003875A IT201800003875A IT201800003875A1 IT 201800003875 A1 IT201800003875 A1 IT 201800003875A1 IT 102018000003875 A IT102018000003875 A IT 102018000003875A IT 201800003875 A IT201800003875 A IT 201800003875A IT 201800003875 A1 IT201800003875 A1 IT 201800003875A1
Authority
IT
Italy
Prior art keywords
hgfr
human
extracellular portion
antibody fragment
combination
Prior art date
Application number
IT102018000003875A
Other languages
English (en)
Italian (it)
Inventor
Cristina Basilico
Elisa Vigna
Paolo Maria Comoglio
Original Assignee
Metis Prec Medicine Sb S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metis Prec Medicine Sb S R L filed Critical Metis Prec Medicine Sb S R L
Priority to IT102018000003875A priority Critical patent/IT201800003875A1/it
Priority to CN201980020753.XA priority patent/CN112041340A/zh
Priority to SG11202008612XA priority patent/SG11202008612XA/en
Priority to CA3093513A priority patent/CA3093513A1/en
Priority to AU2019240274A priority patent/AU2019240274B2/en
Priority to EP19721054.5A priority patent/EP3768710A1/en
Priority to PCT/IB2019/052307 priority patent/WO2019180658A1/en
Priority to US16/982,330 priority patent/US11814433B2/en
Priority to BR112020018981A priority patent/BR112020018981A8/pt
Priority to JP2021500367A priority patent/JP7381555B2/ja
Priority to RU2020129465A priority patent/RU2788606C2/ru
Priority to MX2020009787A priority patent/MX2020009787A/es
Priority to KR1020207030214A priority patent/KR20200135449A/ko
Publication of IT201800003875A1 publication Critical patent/IT201800003875A1/it
Priority to IL277476A priority patent/IL277476B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102018000003875A 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi IT201800003875A1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT102018000003875A IT201800003875A1 (it) 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
US16/982,330 US11814433B2 (en) 2018-03-22 2019-03-21 Combination of anti-HGFR antibody and HEGFR for the treatment of a tumor and/or metastasis
BR112020018981A BR112020018981A8 (pt) 2018-03-22 2019-03-21 Combinação de anticorpo anti-hgfr e hegfr para o tratamento de um tumor e/ou metástase
CA3093513A CA3093513A1 (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis
AU2019240274A AU2019240274B2 (en) 2018-03-22 2019-03-21 Combination of anti-HGFR antibody and hEGFR for the treatment of a tumor and/or metastasis
EP19721054.5A EP3768710A1 (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis
PCT/IB2019/052307 WO2019180658A1 (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis
CN201980020753.XA CN112041340A (zh) 2018-03-22 2019-03-21 用于治疗肿瘤和/或转移的抗ghfr抗体和hegfr的组合
SG11202008612XA SG11202008612XA (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis
JP2021500367A JP7381555B2 (ja) 2018-03-22 2019-03-21 腫瘍および／または転移の治療のための抗－ｈｇｆｒ抗体およびｈｅｇｆｒの組み合わせ
RU2020129465A RU2788606C2 (ru) 2018-03-22 2019-03-21 Комбинация антитела против hgfr и hegfr для лечения опухоли и/или метастаза
MX2020009787A MX2020009787A (es) 2018-03-22 2019-03-21 Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis.
KR1020207030214A KR20200135449A (ko) 2018-03-22 2019-03-21 종양 및/또는 전이의 치료를 위한 항-hgfr 항체 및 hegfr의 조합
IL277476A IL277476B1 (en) 2018-03-22 2020-09-21 Combination of anti-hepatocyte growth hormone receptor antibody and human epidermal growth hormone receptor hepatocyte for the treatment of cancer and/or metastasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000003875A IT201800003875A1 (it) 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi

Publications (1)

Publication Number Publication Date
IT201800003875A1 true IT201800003875A1 (it) 2019-09-22

Family

ID=62530500

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102018000003875A IT201800003875A1 (it) 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi

Country Status (13)

Country Link
US (1) US11814433B2 (https=)
EP (1) EP3768710A1 (https=)
JP (1) JP7381555B2 (https=)
KR (1) KR20200135449A (https=)
CN (1) CN112041340A (https=)
AU (1) AU2019240274B2 (https=)
BR (1) BR112020018981A8 (https=)
CA (1) CA3093513A1 (https=)
IL (1) IL277476B1 (https=)
IT (1) IT201800003875A1 (https=)
MX (1) MX2020009787A (https=)
SG (1) SG11202008612XA (https=)
WO (1) WO2019180658A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017135251A1 (ja) * 2016-02-02 2017-08-10 国立研究開発法人物質・材料研究機構 強磁性トンネル接合体、これを用いた磁気抵抗効果素子及びスピントロニクスデバイス並びに強磁性トンネル接合体の製造方法
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025188676A1 (en) * 2024-03-04 2025-09-12 The Board Of Trustees Of The Leland Stanford Junior University Genetic engineering of cells for secretion of therapeutic antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090807A1 (en) * 2006-02-06 2007-08-16 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
WO2014108829A1 (en) * 2013-01-09 2014-07-17 Metheresis Translational Research S.A. New antibody fragments, compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006018354D1 (de) * 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
CN101914161B (zh) * 2010-08-13 2013-12-11 四川大学 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090807A1 (en) * 2006-02-06 2007-08-16 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
WO2014108829A1 (en) * 2013-01-09 2014-07-17 Metheresis Translational Research S.A. New antibody fragments, compositions and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
C.MODICA ET AL.: "Vertical inhibition of Met by dual decoy/antibody strategy", 2ND EACR-OECI CONFERENCE, ABSTR.36, 13 March 2017 (2017-03-13) - 16 March 2017 (2017-03-16), XP002786870 *
CRISTINA BASILICO ET AL: "Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy : Vertical inhibition of the HGF/MET axis", INTERNATIONAL JOURNAL OF CANCER, vol. 143, no. 7, 25 April 2018 (2018-04-25), US, pages 1774 - 1785, XP055527355, ISSN: 0020-7136, DOI: 10.1002/ijc.31550 *
GIOVANNI PACCHIANA ET AL: "Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 285, no. 46, 12 November 2010 (2010-11-12), pages 36149 - 36157, XP002621766, ISSN: 0021-9258, [retrieved on 20100910], DOI: 10.1074/JBC.M110.134031 *
MICHIELI P ET AL: "Targeting the tumor and its microenvironment by a dual-function decoy Met receptor", CANCER CELL, CELL PRESS, US, vol. 6, no. 1, 1 July 2004 (2004-07-01), pages 61 - 73, XP002389313, ISSN: 1535-6108, DOI: 10.1016/J.CCR.2004.05.032 *
PETRELLI A ET AL: "Ab-induced ectodomain shedding mediates hepatocytes growth factor receptor down-regulation and hampers biological activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, NATIONAL ACADEMY OF SCIENCES, US, vol. 103, no. 13, 28 March 2006 (2006-03-28), pages 5090 - 5095, XP002389316, ISSN: 0027-8424, DOI: 10.1073/PNAS.0508156103 *
Z. TIRAN ET AL: "A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway", CLINICAL CANCER RESEARCH, vol. 14, no. 14, 15 July 2008 (2008-07-15), pages 4612 - 4621, XP055147844, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-0108 *

Also Published As

Publication number Publication date
JP2021518170A (ja) 2021-08-02
BR112020018981A2 (pt) 2021-01-05
SG11202008612XA (en) 2020-10-29
AU2019240274B2 (en) 2025-04-24
IL277476B1 (en) 2026-01-01
JP7381555B2 (ja) 2023-11-15
IL277476A (en) 2020-11-30
EP3768710A1 (en) 2021-01-27
CA3093513A1 (en) 2019-09-26
US11814433B2 (en) 2023-11-14
BR112020018981A8 (pt) 2022-06-28
CN112041340A (zh) 2020-12-04
AU2019240274A1 (en) 2020-10-15
MX2020009787A (es) 2020-11-09
US20210070868A1 (en) 2021-03-11
KR20200135449A (ko) 2020-12-02
RU2020129465A (ru) 2022-04-22
WO2019180658A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
ES2825576T3 (es) Neutralización de rutas inhibidoras en linfocitos
KR101429297B1 (ko) 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물
Jenkins et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo
KR20190126003A (ko) Ros1 키나제 억제제로서의 매크로시클릭 화합물
KR20070031871A (ko) Ｅｇｆ 수용체 에피토프 펩타이드 및 이의 용도
ES2674491T3 (es) Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos
Basilico et al. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody‐“decoy” strategy
US11814433B2 (en) Combination of anti-HGFR antibody and HEGFR for the treatment of a tumor and/or metastasis
TW200948380A (en) Combination of HGF inhibitor and PTEN agonist to treat cancer
AU2026201438A1 (en) Anti-met fab-fc for the treatment of a tumor and/or metastasis
EP3440111B1 (en) Anti-vegfr-1 antibodies and uses thereof
RU2788606C2 (ru) Комбинация антитела против hgfr и hegfr для лечения опухоли и/или метастаза
Benvenuti et al. Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer
HK40119612A (zh) 用於治疗肿瘤和/或转移的抗met fab-fc
Modica MET/HGF co-targeting: a tool to provide insight into the tumour progression